DOCSLIB.ORG

Protein Kinase

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Protein Kinase Flexi® ORF Clone www.promega.co.jp/flexiclone/ Protein Kinase 355個 （2012/4/1 現在） 遺伝子シンボル 説明 FXC_PID 価格 FHC_PID 価格 AAK1 AP2 associated kinase 1 FXC00722 ¥40,000 FHC00722 ¥50,000 AATK apoptosis-associated tyrosine kinase FXC04004 ¥40,000 FHC04004M ¥60,000 ABL1 c-abl oncogene 1, receptor tyrosine kinase FXC01406 ¥40,000 FHC01406 ¥50,000 ACTR2 ARP2 actin-related protein 2 homolog (yeast) FXC02146 ¥40,000 FHC02146 ¥50,000 Activin receptor type-1 Precursor (EC 2.7.11.30)(Activin receptor type I)(ACTR-I)(Serine/threonine-protein kinase ACVR1 FXC03971 ¥40,000 FHC03971 ¥50,000 receptor R1)(SKR1)(Activin receptor-like kinase 2)(ALK- 2)(TGF-B superfamily receptor type I)(TSR-I) ACVR1B activin A receptor, type IB FXC01408 ¥40,000 FHC01408 ¥50,000 ACVR1C activin A receptor, type IC FXC09109M ¥50,000 FHC09109 ¥50,000 ACVRL1 activin A receptor type II-like 1, transcript variant 1 FXC28135M ¥50,000 FHC28135 ¥50,000 ADRBK1 adrenergic, beta, receptor kinase 1 FXC09648M ¥50,000 FHC09648 ¥50,000 ADRBK2 adrenergic, beta, receptor kinase 2 FXC27231M ¥50,000 FHC27231 ¥50,000 AKT1 v-akt murine thymoma viral oncogene homolog 1 FXC02215 ¥40,000 FHC02215 ¥50,000 AKT2 v-akt murine thymoma viral oncogene homolog 2 FXC26633 ¥40,000 FHC26633 ¥50,000 v-akt murine thymoma viral oncogene homolog 3 (protein AKT3 FXC02812 ¥40,000 FHC02812 ¥50,000 kinase B, gamma) ALK anaplastic lymphoma receptor tyrosine kinase FXC00337 ¥40,000 FHC00337 ¥50,000 A-Raf proto-oncogene serine/threonine-protein kinase (EC ARAF FXC08066 ¥40,000 FHC08066 ¥50,000 2.7.11.1)(A-raf-1)(Proto-oncogene Pks) AURKA aurora kinase A FXC02742 ¥40,000 FHC02742 ¥50,000 AURKC aurora kinase C FXC11256 ¥40,000 FHC11256 ¥50,000 AXL AXL receptor tyrosine kinase FXC01861 ¥40,000 FHC01861 ¥50,000 Tyrosine-protein kinase BLK (EC 2.7.10.2)(B lymphocyte BLK FXC03808 ¥40,000 FHC03808 ¥50,000 kinase)(p55-BLK) BMPR1A bone morphogenetic protein receptor, type IA FXC09257 ¥40,000 FHC09257 ¥50,000 Bone morphogenetic protein receptor type-1B Precursor (EC BMPR1B FXC03435 ¥40,000 FHC03435 ¥50,000 2.7.11.30)(CDw293 antigen) bone morphogenetic protein receptor, type II (serine/threonine BMPR2 FXC01318 ¥40,000 FHC01318 ¥50,000 kinase) BMX BMX non-receptor tyrosine kinase FXC08849 ¥40,000 FHC08849 ¥50,000 B-Raf proto-oncogene serine/threonine-protein kinase (EC BRAF FXC11883 ¥40,000 FHC11883 ¥50,000 2.7.11.1)(p94)(v-Raf murine sarcoma viral oncogene homolog BRSK2 BR serine/threonine kinase 2 FXC29626M ¥50,000 FHC29626 ¥50,000 Tyrosine-protein kinase BTK (EC 2.7.10.2)(Bruton tyrosine BTK kinase)(Agammaglobulinaemia tyrosine kinase)(ATK)(B-cell FXC05404M ¥50,000 FHC05404 ¥50,000 progenitor kinase)(BPK) CAMK1 calcium/calmodulin-dependent protein kinase I FXC11206 ¥40,000 FHC11206 ¥50,000 CAMK1D calcium/calmodulin-dependent protein kinase ID FXC11216 ¥40,000 FHC11216 ¥50,000 CAMK2A calcium/calmodulin-dependent protein kinase II alpha FXC00158 ¥40,000 FHC00158 ¥50,000 CAMK2B calcium/calmodulin-dependent protein kinase II beta FXC04424 ¥40,000 FHC04424 ¥50,000 CAMK2D calcium/calmodulin-dependent protein kinase II delta FXC01765 ¥40,000 FHC01765 ¥50,000 CAMK2G calcium/calmodulin-dependent protein kinase II gamma FXC10307M ¥50,000 FHC10307 ¥50,000 CAMK4 calcium/calmodulin-dependent protein kinase IV FXC11417 ¥40,000 FHC11417 ¥50,000 CAMKK1 calcium/calmodulin-dependent protein kinase kinase 1, alpha FXC10271M ¥50,000 FHC10271 ¥50,000 CAMKK2 calcium/calmodulin-dependent protein kinase kinase 2, beta FXC09184M ¥50,000 FHC09184 ¥50,000 CAMKV CaM kinase-like vesicle-associated FXC07876M ¥50,000 FHC07876 ¥50,000 Peripheral plasma membrane protein CASK (hCASK)(EC CASK 2.7.11.1)(Calcium/calmodulin-dependent serine protein FXC04437M ¥50,000 FHC04437 ¥50,000 kinase)(Lin-2 homolog) CDC42BPA CDC42 binding protein kinase alpha (DMPK-like) FXC01284 ¥40,000 FHC01284 ¥50,000 CDC42BPB CDC42 binding protein kinase beta (DMPK-like) FXC00181 ¥40,000 FHC00181 ¥50,000 CDC7 cell division cycle 7 homolog (S. cerevisiae) FXC10990M ¥50,000 FHC10990 ¥50,000 CDK10 cyclin-dependent kinase 10 FXC02837 ¥40,000 FHC02837 ¥50,000 CDK11A cyclin-dependent kinase 11A FXC11114M ¥50,000 FHC11114 ¥50,000 CDK12 cyclin-dependent kinase 12 (CDK12), transcript variant 2, FXC02002 ¥40,000 FHC02002 ¥50,000 CDK12 cyclin-dependent kinase 12, transcript variant 1 FXC25993M ¥120,000 FHC25993M ¥130,000 CDK15 cyclin-dependent kinase 15 FXC11569M ¥50,000 FHC11569 ¥50,000 CDK17 cyclin-dependent kinase 17, transcript variant 1 FXC09466M ¥50,000 FHC09466 ¥50,000 CDK2 cyclin-dependent kinase 2 FXC02738 ¥40,000 FHC02738 ¥50,000 CDK20 cyclin-dependent kinase 20, transcript variant 3 FXC23550M ¥50,000 FHC23550 ¥50,000 CDK3 Cell division protein kinase 3 (EC 2.7.11.22) FXC03928 ¥40,000 FHC03928 ¥50,000 Cell division protein kinase 4 (EC 2.7.11.22)(Cyclin- CDK4 FXC08159 ¥40,000 FHC08159 ¥50,000 dependent kinase 4)(PSK-J3) CDK5 cyclin-dependent kinase 5 FXC02662 ¥40,000 FHC02662 ¥50,000 CDK6 cyclin-dependent kinase 6 FXC10565 ¥40,000 FHC10565 ¥50,000 CDK7 cyclin-dependent kinase 7 FXC01723 ¥40,000 FHC01723 ¥50,000 CDK8 cyclin-dependent kinase 8 FXC24966M ¥50,000 FHC24966 ¥50,000 プロメガ株式会社 TEL. 03-3669-7981 納期はProduct ID (PID)が赤色のものは約2ヶ月、その他は約２週間です。 Flexi® ORF Clone www.promega.co.jp/flexiclone/ CDK9 cyclin-dependent kinase 9 FXC08042M ¥50,000 FHC08042 ¥50,000 CDKL1 cyclin-dependent kinase-like 1 (CDC2-related kinase) FXC25164M ¥50,000 FHC25164 ¥50,000 CDKL2 cyclin-dependent kinase-like 2 (CDC2-related kinase) FXC21962M ¥50,000 FHC21962 ¥50,000 CDKL3 cyclin-dependent kinase-like 3, transcript variant 1 FXC31101M ¥50,000 FHC31101 ¥50,000 CDKL4 cyclin-dependent kinase-like 4 FXC28701M ¥50,000 FHC28701 ¥50,000 CDKL5 cyclin-dependent kinase-like 5 FXC10738 ¥40,000 FHC10738 ¥50,000 CHEK1 Serine/threonine-protein kinase Chk1 (EC 2.7.11.1) FXC03424 ¥40,000 FHC03424 ¥50,000 CHEK2 Serine/threonine-protein kinase Chk2 (EC 2.7.11.1)(Cds1) FXC04554 ¥40,000 FHC04554 ¥50,000 CHUK conserved helix-loop-helix ubiquitous kinase FXC10858M ¥50,000 FHC10858 ¥50,000 CIT citron (rho-interacting, serine/threonine kinase 21) FXC00156 ¥40,000 FHC00156 ¥50,000 CSF1R colony stimulating factor 1 receptor FXC10479 ¥40,000 FHC10479 ¥50,000 Tyrosine-protein kinase CSK (EC 2.7.10.2)(C-SRC CSK FXC03488 ¥40,000 FHC03488 ¥50,000 kinase)(Protein-tyrosine kinase CYL) CSNK1A1 casein kinase 1, alpha 1 FXC01538 ¥40,000 FHC01538 ¥50,000 CSNK1A1L casein kinase 1, alpha 1-like FXC09266 ¥40,000 FHC09266 ¥50,000 CSNK1D Casein kinase I isoform delta (CKI-delta)(CKId)(EC 2.7.11.1) FXC03511 ¥40,000 FHC03511 ¥50,000 CSNK1E casein kinase 1, epsilon FXC01335 ¥40,000 FHC01335 ¥50,000 CSNK1G1 casein kinase 1, gamma 1 FXC11258 ¥40,000 FHC11258 ¥50,000 CSNK1G2 casein kinase 1, gamma 2 FXC11254 ¥40,000 FHC11254 ¥50,000 CSNK1G3 Casein kinase I isoform gamma-3 (CKI-gamma 3)(EC FXC10431 ¥40,000 FHC10431 ¥50,000 CSNK2A1 casein kinase 2, alpha 1 polypeptide FXC08568M ¥50,000 FHC08568 ¥50,000 CSNK2A2 casein kinase 2, alpha prime polypeptide FXC04660 ¥40,000 FHC04660 ¥50,000 DAPK1 death-associated protein kinase 1 FXC01854 ¥40,000 FHC01854 ¥50,000 DAPK2 death-associated protein kinase 2 FXC25418M ¥50,000 FHC25418 ¥50,000 DAPK3 death-associated protein kinase 3 FXC26400M ¥50,000 FHC26400 ¥50,000 DCLK1 doublecortin-like kinase 1 FXC00061 ¥40,000 FHC00061 ¥50,000 DCLK2 doublecortin-like kinase 2 FXC01748 ¥40,000 FHC01748 ¥50,000 DDR1 discoidin domain receptor tyrosine kinase 1 FXC02069 ¥40,000 FHC02069 ¥50,000 DMPK dystrophia myotonica-protein kinase FXC01383 ¥40,000 FHC01383 ¥50,000 DYRK1B dual-specificity tyrosine-(Y)-phosphorylation regulated kinase FXC01350 ¥40,000 FHC01350 ¥50,000 Dual specificity tyrosine-phosphorylation-regulated kinase 2 DYRK2 FXC03899 ¥40,000 FHC03899 ¥50,000 (EC 2.7.12.1) DYRK3 dual-specificity tyrosine-(Y)-phosphorylation regulated kinase FXC11427 ¥40,000 FHC11427 ¥50,000 DYRK4 dual-specificity tyrosine-(Y)-phosphorylation regulated kinase FXC11424 ¥40,000 FHC11424 ¥50,000 epidermal growth factor receptor (erythroblastic leukemia viral EGFR FXC09683M ¥110,000 FHC09683M ¥120,000 (v-erb-b) oncogene homolog, avian) EIF2AK1 Eukaryotic translation initiation factor 2-alpha kinase 1 FXC00817 ¥40,000 FHC00817 ¥50,000 eukaryotic translation initiation factor 2-alpha kinase 2, EIF2AK2 FXC20967M ¥50,000 FHC20967 ¥50,000 transcript variant 2 eukaryotic translation initiation factor 2-alpha kinase 2, EIF2AK2 FXC20968M ¥50,000 FHC20968M ¥60,000 transcript variant 3 EIF2AK4 eukaryotic translation initiation factor 2 alpha kinase 4 FXC04866 ¥40,000 FHC04866 ¥50,000 EPHA2 EPH receptor A2 FXC09635M ¥50,000 FHC09635 ¥50,000 EPHA3 EPH receptor A3 FXC01711 ¥40,000 FHC01711 ¥50,000 EPHA5 EPH receptor A5 FXC01385 ¥40,000 FHC01385 ¥50,000 EPHA7 EPH receptor A7 FXC10471 ¥40,000 FHC10471 ¥50,000 EPHA8 EPH receptor A8 FXC04904 ¥40,000 FHC04904 ¥50,000 EPHB1 EPH receptor B1 FXC31004M ¥50,000 FHC31004 ¥50,000 EPHB2 EPH receptor B2 FXC01018 ¥40,000 FHC01018 ¥50,000 EPHB3 EPH receptor B3 FXC01841 ¥40,000 FHC01841 ¥50,000 EPHB4 EPH receptor B4 FXC23022M ¥50,000 FHC23022 ¥50,000 EPHB6 EPH receptor B6 FXC01198 ¥40,000 FHC01198 ¥50,000 Receptor tyrosine-protein kinase erbB-2 Precursor (EC ERBB2 2.7.10.1)(p185erbB2)(C-erbB-2)(NEU proto- FXC11836 ¥40,000 FHC11836M ¥60,000 oncogene)(Tyrosine kinase-type cell surface receptor v-erb-b2 erythroblastic leukemia viral oncogene homolog 3 ERBB3 FXC28149M ¥50,000 FHC28149 ¥50,000 (avian), transcript variant 1 Homo sapiens v-erb-a erythroblastic leukemia viral oncogene ERBB4 FXC21305M ¥110,000 FHC21305M ¥120,000 homolog 4 (avian) (ERBB4), transcript variant JM-a/CVT-1 Homo sapiens v-erb-a erythroblastic leukemia viral
Load more

Recommended publications
  • Mir-338-3P Functions As a Tumor Suppressor in Gastric Cancer by Targeting PTP1B
    Sun et al. Cell Death and Disease DOI 10.1038/s41419-018-0611-0 Cell Death & Disease ARTICLE Open Access miR-338-3p functions as a tumor suppressor in gastric cancer by targeting PTP1B Feng Sun1, Mengchao Yu2,JingYu2, Zhijian Liu1,XinyanZhou2,YanqingLiu2, Xiaolong Ge3,HaidongGao2, Mei Li4, Xiaohong Jiang2,SongLiu1,XiChen2 and Wenxian Guan 1 Abstract Gastric cancer (GC) is one of the most common malignant tumors and peritoneal metastasis is the primary cause for advanced GC’s mortality. Protein-tyrosine phosphatase 1B (PTP1B) functions as an oncogene and involves in carcinogenesis and cancer dissemination. However, the function and regulation of PTP1B in GC remain poorly understood. In this study, we found that PTP1B was upregulated in GC tissues and overexpression of PTP1B in vitro promoted cell migration and prevented apoptosis. Then, we predicted that PTP1B was a target of miR-338-3p and we revealed an inverse correlation between miR-338-3p levels and PTP1B protein levels in GC tissues. Next, we verified that PTP1B was inhibited by miR-338-3p via direct targeting to its 3′-untranslated regions. Moreover, overexpression of miR-338-3p in vitro attenuated GC cell migration and promoted apoptosis, and these effects could be partially reversed by reintroduction of PTP1B. Finally, we established an orthotopic xenograft model and a peritoneal dissemination model of GC to demonstrate that miR-338-3p restrained tumor growth and dissemination in vivo by targeting PTP1B. Taken together, our results highlight that PTP1B is an oncogene and is negatively regulated by miR- 1234567890():,; 1234567890():,; 338-3p in GC, which may provide new insights into novel molecular therapeutic targets for GC.
    [Show full text]
  • ACVR1 Antibody Cat
    ACVR1 Antibody Cat. No.: 4791 Western blot analysis of ACVR1 in A549 cell lysate with ACVR1 antibody at 1 μg/mL in (A) the absence and (B) the presence of blocking peptide. Specifications HOST SPECIES: Rabbit SPECIES REACTIVITY: Human, Mouse HOMOLOGY: Predicted species reactivity based on immunogen sequence: Bovine: (100%), Rat: (93%) ACVR1 antibody was raised against a 14 amino acid synthetic peptide near the amino terminus of the human ACVR1. IMMUNOGEN: The immunogen is located within the first 50 amino acids of ACVR1. TESTED APPLICATIONS: ELISA, WB ACVR1 antibody can be used for detection of ACVR1 by Western blot at 1 μg/mL. APPLICATIONS: Antibody validated: Western Blot in human samples. All other applications and species not yet tested. At least four isoforms of ACVR1 are known to exist. This antibody is predicted to have no SPECIFICITY: cross-reactivity to ACVR1B or ACVR1C. POSITIVE CONTROL: 1) Cat. No. 1203 - A549 Cell Lysate Properties October 1, 2021 1 https://www.prosci-inc.com/acvr1-antibody-4791.html PURIFICATION: ACVR1 Antibody is affinity chromatography purified via peptide column. CLONALITY: Polyclonal ISOTYPE: IgG CONJUGATE: Unconjugated PHYSICAL STATE: Liquid BUFFER: ACVR1 Antibody is supplied in PBS containing 0.02% sodium azide. CONCENTRATION: 1 mg/mL ACVR1 antibody can be stored at 4˚C for three months and -20˚C, stable for up to one STORAGE CONDITIONS: year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures. Additional Info OFFICIAL SYMBOL: ACVR1 ACVR1 Antibody: FOP, ALK2, SKR1, TSRI, ACTRI, ACVR1A, ACVRLK2, Activin receptor type-1, ALTERNATE NAMES: Activin receptor type I, ACTR-I ACCESSION NO.: NP_001096 PROTEIN GI NO.: 4501895 GENE ID: 90 USER NOTE: Optimal dilutions for each application to be determined by the researcher.
    [Show full text]
  • Katalog 2015 Cover Paul Lin *Hinweis Förderung.Indd
    Product List 2015 WE LIVE SERVICE Certificates quartett owns two productions sites that are certified according to EN ISO 9001:2008 Quality management systems - Requirements EN ISO 13485:2012 + AC:2012 Medical devices - Quality management systems - Requirements for regulatory purposes GMP Conformity Our quality management guarantees products of highest quality! 2 Foreword to the quartett product list 2015 quartett Immunodiagnostika, Biotechnologie + Kosmetik Vertriebs GmbH welcomes you as one of our new business partners as well as all of our previous loyal clients. You are now member of quartett´s worldwide customers. First of all we would like to introduce ourselves to you. Founded as a family-run company in 1986, quartett ensures for more than a quarter of a century consistent quality of products. Service and support of our valued customers are our daily businesses. And we will continue! In the end 80´s quartett offered radioimmunoassay and enzyme immunoassay kits from different manufacturers in the USA. In the beginning 90´s the company changed its strategy from offering products for routine diagnostic to the increasing field of research and development. Setting up a production plant in 1997 and a second one in 2011 supported this decision. The company specialized its product profile in the field of manufacturing synthetic peptides for antibody production, peptides such as protease inhibitors, biochemical reagents and products for histology, cytology and immunohistology. All products are exclusively manufactured in Germany without outsourcing any production step. Nowadays, we expand into all other diagnostic and research fields and supply our customers in universities, government institutes, pharmaceutical and biotechnological companies, hospitals, and private doctor offices.
    [Show full text]
  • Saracatinib Is an Efficacious Clinical Candidate for Fibrodysplasia Ossificans Progressiva
    RESEARCH ARTICLE Saracatinib is an efficacious clinical candidate for fibrodysplasia ossificans progressiva Eleanor Williams,1 Jana Bagarova,2 Georgina Kerr,1 Dong-Dong Xia,2 Elsie S. Place,3 Devaveena Dey,2 Yue Shen,2 Geoffrey A. Bocobo,2 Agustin H. Mohedas,2 Xiuli Huang,4 Philip E. Sanderson,4 Arthur Lee,4 Wei Zheng,4 Aris N. Economides,5 James C. Smith,3 Paul B. Yu,2 and Alex N. Bullock1 1Centre for Medicines Discovery, University of Oxford, Oxford, United Kingdom. 2Department of Medicine, Cardiovascular Division, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts, USA. 3Developmental Biology Laboratory, Francis Crick Institute, London, United Kingdom. 4National Center for Advancing Translational Sciences, NIH, Bethesda, Maryland, USA. 5Regeneron Pharmaceuticals Inc., Tarrytown, New York, USA. Currently, no effective therapies exist for fibrodysplasia ossificans progressiva (FOP), a rare congenital syndrome in which heterotopic bone is formed in soft tissues owing to dysregulated activity of the bone morphogenetic protein (BMP) receptor kinase ALK2 (also known as ACVR1). From a screen of known biologically active compounds, we identified saracatinib as a potent ALK2 kinase inhibitor. In enzymatic and cell-based assays, saracatinib preferentially inhibited ALK2, compared with other receptors of the BMP/TGF-β signaling pathway, and induced dorsalization in zebrafish embryos consistent with BMP antagonism. We further tested the efficacy of saracatinib using an inducible ACVR1Q207D-transgenic mouse line, which provides a model of heterotopic ossification (HO), as well as an inducible ACVR1R206H-knockin mouse, which serves as a genetically and physiologically faithful FOP model. In both models, saracatinib was well tolerated and potently inhibited the development of HO, even when administered transiently following soft tissue injury.
    [Show full text]
  • Datasheet BA3564-2 Anti-FES Antibody
    Product datasheet Anti-FES Antibody Catalog Number: BA3564-2 BOSTER BIOLOGICAL TECHNOLOGY Special NO.1, International Enterprise Center, 2nd Guanshan Road, Wuhan, China Web: www.boster.com.cn Phone: +86 27 67845390 Fax: +86 27 67845390 Email: [email protected] Basic Information Product Name Anti-FES Antibody Gene Name FES Source Rabbit IgG Species Reactivity human,mouse,rat Tested Application WB Contents 500ug/ml antibody with PBS ，0.02% NaN3 , 1mg BSA and 50% glycerol. Immunogen A synthetic peptide corresponding to a sequence at the C-terminus of human FES(808-822aa STIYQELQSIRKRHR). Purification Immunogen affinity purified. Observed MW Dilution Ratios Western blot: 1:500-2000 Storage 12 months from date of receipt，-20℃ as supplied.6 months 2 to 8℃ after reconstitution. Avoid repeated freezing and thawing Background Information FES(feline sarcoma oncogene) is an enzyme that in humans is encoded by the FES gene, also known as Proto-oncogene tyrosine-protein kinase Fes/Fps, Feline sarcoma/Fujinami avian sarcoma oncogene homolog, Proto-oncogene c-Fes, Proto-oncogene c-Fps, p93c-fes c-fes/fps protein, FPS, Oncogene FES, feline sarcoma virus, FPS. This gene encodes the human cellular counterpart of a feline sarcoma retrovirus protein with transforming capabilities. Non-onc intervening sequences were present in the human counterpart. The gene product has tyrosine-specific protein kinase activity and that activity is required for maintenance of°Cellular transformation. Its chromosomal location has linked it to a specific translocation event identified in patients with acute promyelocytic leukemia, but it is also involved in normal hematopoiesis. A truncated transcript has been identified that is generated utilizing a start site in one of the far downstream exons but a protein product associated with this transcript has not been identified.
    [Show full text]
  • Pancancer Progression Human Vjune2017
    Gene Symbol Accession Alias/Prev Symbol Official Full Name AAMP NM_001087.3 - angio-associated, migratory cell protein ABI3BP NM_015429.3 NESHBP|TARSH ABI family, member 3 (NESH) binding protein ACHE NM_000665.3 ACEE|ARACHE|N-ACHE|YT acetylcholinesterase ACTG2 NM_001615.3 ACT|ACTA3|ACTE|ACTL3|ACTSG actin, gamma 2, smooth muscle, enteric ACVR1 NM_001105.2 ACTRI|ACVR1A|ACVRLK2|ALK2|FOP|SKR1|TSRI activin A receptor, type I ACVR1C NM_145259.2 ACVRLK7|ALK7 activin A receptor, type IC ACVRL1 NM_000020.1 ACVRLK1|ALK-1|ALK1|HHT|HHT2|ORW2|SKR3|TSR-I activin A receptor type II-like 1 ADAM15 NM_207195.1 MDC15 ADAM metallopeptidase domain 15 ADAM17 NM_003183.4 ADAM18|CD156B|CSVP|NISBD|TACE ADAM metallopeptidase domain 17 ADAM28 NM_014265.4 ADAM 28|ADAM23|MDC-L|MDC-Lm|MDC-Ls|MDCL|eMDC II|eMDCII ADAM metallopeptidase domain 28 ADAM8 NM_001109.4 CD156|MS2 ADAM metallopeptidase domain 8 ADAM9 NM_001005845.1 CORD9|MCMP|MDC9|Mltng ADAM metallopeptidase domain 9 ADAMTS1 NM_006988.3 C3-C5|METH1 ADAM metallopeptidase with thrombospondin type 1 motif, 1 ADAMTS12 NM_030955.2 PRO4389 ADAM metallopeptidase with thrombospondin type 1 motif, 12 ADAMTS8 NM_007037.4 ADAM-TS8|METH2 ADAM metallopeptidase with thrombospondin type 1 motif, 8 ADAP1 NM_006869.2 CENTA1|GCS1L|p42IP4 ArfGAP with dual PH domains 1 ADD1 NM_001119.4 ADDA adducin 1 (alpha) ADM2 NM_001253845.1 AM2|dJ579N16.4 adrenomedullin 2 ADRA2B NM_000682.4 ADRA2L1|ADRA2RL1|ADRARL1|ALPHA2BAR|alpha-2BAR adrenoceptor alpha 2B AEBP1 NM_001129.3 ACLP AE binding protein 1 AGGF1 NM_018046.3 GPATC7|GPATCH7|HSU84971|HUS84971|VG5Q
    [Show full text]
  • ACVR1C Antibody Cat
    ACVR1C Antibody Cat. No.: 4795 ACVR1C Antibody Specifications HOST SPECIES: Rabbit SPECIES REACTIVITY: Human, Mouse, Rat ACVR1C antibody was raised against a 15 amino acid synthetic peptide near the amino terminus of the human ACVR1C. IMMUNOGEN: The immunogen is located within amino acids 130 - 180 of ACVR1C. TESTED APPLICATIONS: ELISA, WB ACVR1C antibody can be used for detection of ACVR1C by Western blot at 1 and 2 μg/mL. APPLICATIONS: Antibody validated: Western Blot in human samples. All other applications and species not yet tested. SPECIFICITY: This antibody is predicted to have no cross-reactivity to ACVR1 or ACVR1B. POSITIVE CONTROL: 1) Cat. No. 1309 - Human Placenta Tissue Lysate Properties PURIFICATION: ACVR1C Antibody is affinity chromatography purified via peptide column. CLONALITY: Polyclonal September 25, 2021 1 https://www.prosci-inc.com/acvr1c-antibody-4795.html ISOTYPE: IgG CONJUGATE: Unconjugated PHYSICAL STATE: Liquid BUFFER: ACVR1C Antibody is supplied in PBS containing 0.02% sodium azide. CONCENTRATION: 1 mg/mL ACVR1C antibody can be stored at 4˚C for three months and -20˚C, stable for up to one STORAGE CONDITIONS: year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures. Additional Info OFFICIAL SYMBOL: ACVR1 ACVR1C Antibody: FOP, ALK2, SKR1, TSRI, ACTRI, ACVR1A, ACVRLK2, Activin receptor ALTERNATE NAMES: type-1, Activin receptor type I, ACTR-I ACCESSION NO.: Q8NER5 PROTEIN GI NO.: 4501895 GENE ID: 90 USER NOTE: Optimal dilutions for each application to be determined by the researcher. Background and References ACVR1C Antibody: Activins are dimeric growth and differentiation factors which belong to the transforming growth factor-beta (TGF-beta) superfamily of structurally related signaling proteins.
    [Show full text]
  • Ponatinib Shows Potent Antitumor Activity in Small Cell Carcinoma of the Ovary Hypercalcemic Type (SCCOHT) Through Multikinase Inhibition Jessica D
    Published OnlineFirst February 9, 2018; DOI: 10.1158/1078-0432.CCR-17-1928 Cancer Therapy: Preclinical Clinical Cancer Research Ponatinib Shows Potent Antitumor Activity in Small Cell Carcinoma of the Ovary Hypercalcemic Type (SCCOHT) through Multikinase Inhibition Jessica D. Lang1,William P.D. Hendricks1, Krystal A. Orlando2, Hongwei Yin1, Jeffrey Kiefer1, Pilar Ramos1, Ritin Sharma3, Patrick Pirrotte3, Elizabeth A. Raupach1,3, Chris Sereduk1, Nanyun Tang1, Winnie S. Liang1, Megan Washington1, Salvatore J. Facista1, Victoria L. Zismann1, Emily M. Cousins4, Michael B. Major4, Yemin Wang5, Anthony N. Karnezis5, Aleksandar Sekulic1,6, Ralf Hass7, Barbara C. Vanderhyden8, Praveen Nair9, Bernard E. Weissman2, David G. Huntsman5,10, and Jeffrey M. Trent1 Abstract Purpose: Small cell carcinoma of the ovary, hypercalcemic type three SWI/SNF wild-type ovarian cancer cell lines. We further (SCCOHT) is a rare, aggressive ovarian cancer in young women identified ponatinib as the most effective clinically approved that is universally driven by loss of the SWI/SNF ATPase subunits RTK inhibitor. Reexpression of SMARCA4 was shown to confer SMARCA4 and SMARCA2. A great need exists for effective targeted a 1.7-fold increase in resistance to ponatinib. Subsequent therapies for SCCOHT. proteomic assessment of ponatinib target modulation in Experimental Design: To identify underlying therapeutic vul- SCCOHT cell models confirmed inhibition of nine known nerabilities in SCCOHT, we conducted high-throughput siRNA ponatinib target kinases alongside 77 noncanonical ponatinib and drug screens. Complementary proteomics approaches pro- targets in SCCOHT. Finally, ponatinib delayed tumor dou- filed kinases inhibited by ponatinib. Ponatinib was tested for bling time 4-fold in SCCOHT-1 xenografts while reducing efficacy in two patient-derived xenograft (PDX) models and one final tumor volumes in SCCOHT PDX models by 58.6% and cell-line xenograft model of SCCOHT.
    [Show full text]
  • Hyperactive and Impulsive Behaviors of LMTK1 Knockout Mice
    www.nature.com/scientificreports OPEN Hyperactive and impulsive behaviors of LMTK1 knockout mice Miyuki Takahashi1,7, Arika Sugiyama1, Ran Wei1, Shizuka Kobayashi2, Kimiko Fukuda3, Hironori Nishino1, Roka Takahashi1, Koji Tsutsumi1,8, Ichiro Kita4, Kanae Ando1, Toshiya Manabe2, Hiroyuki Kamiguchi5, Mineko Tomomura6 & Shin‑ichi Hisanaga1* Lemur tail kinase 1 (LMTK1), previously called Apoptosis‑Associated Tyrosine Kinase (AATYK), remains an uncharacterized Ser/Thr protein kinase that is predominantly expressed in the brain. It is recently reported that LMTK1A, an isoform of LMTK1, binds to recycling endosomes through its palmitoylation and regulates endosomal trafcking by suppressing the activity of Rab11 small GTPase. In neurons, knockdown or knockout of LMTK1 results in longer axons, greater branching of dendrites and increased number of spines, suggesting that LMTK1 plays a role in neuronal circuit formation. However, its in vivo function remained to be investigated. Here, we examined the brain structures and behaviors of LMTK1 knockout (KO) mice. LMTK1 was expressed in most neurons throughout the brain. The overall brain structure appeared to be normal in LMTK1 KO mice, but the numbers of synapses were increased. LMTK1 KO mice had a slight impairment in memory formation and exhibited distinct psychiatric behaviors such as hyperactivity, impulsiveness and high motor coordination without social interaction defcits. Some of these abnormal behaviors represent core features of attention defcit hyperactive disorder (ADHD), suggesting the possible involvement of LMTK1 in the pathogenesis of ADHD. Abbreviations AATYK1 Apoptosis-Associated Tyrosine Kinase ADHD Attention defcit hyperactive disorder Cx Cerebral cortex Cb Cerebellum CS Conditioned stimulus ISH In situ hybridization KO Knockout LMTK Lemur tail kinase PPF Paired-pulse facilitation US Unconditioned stimulus WT Wildtype Neuronal circuit wiring is the structural and functional basis of higher brain activities such as recognition and behaviors.
    [Show full text]
  • Human ALK-7 / ACVR1C Protein (ECD, Fc Tag)
    Human ALK-7 / ACVR1C Protein (ECD, Fc Tag) Catalog Number: 10869-H02H General Information SDS-PAGE: Gene Name Synonym: ACVRLK7; ALK7 Protein Construction: A DNA sequence encoding the human ACVR1C (NP_660302.2) (Met1- Glu113) was expressed with the Fc region of human IgG1 at the C- terminus. Source: Human Expression Host: HEK293 Cells QC Testing Purity: > 95 % as determined by SDS-PAGE. Endotoxin: Protein Description < 1.0 EU per μg protein as determined by the LAL method. ALK-7, also known as ALK7 and ACVR1C, belongs to the ALK family. It is a type I receptor for the TGFB family of signaling molecules. TGF-β is the Stability: prototype of a protein superfamily which, in humans, contains at least 35 members, including activins, inhibins, bone morphogenetic proteins, Samples are stable for up to twelve months from date of receipt at -70 ℃ growth/differentiation factors, and Müllerian inhibiting substance. ALK-7 is a serine-threonine kinase that can cause the activation of one of the SMAD Predicted N terminal: Leu 22 signal transducers, SMAD2. ALK-7 has a ligand known as Nodal. Nodal Molecular Mass: stimulates the secretion of TIMP-1 and inhibits matrix metalloproteinases MMP-2 and MMP-9 activity. The overexpression of Nodal or constitutively The recombinant human ACVR1C consists 330 amino acids and predicts active ALK-7 decreases cell migration and invasion, whereas knock-down a molecular mass of 36.6 kDa. of Nodal and ALK-7 has the opposite effects. Formulation: References Lyophilized from sterile PBS, pH 7.4. 1.Lin YY, et al. (2012) Functional dissection of lysine deacetylases reveals that HDAC1 and p300 regulate AMPK.
    [Show full text]
  • Downloaded from Bioscientifica.Com at 10/03/2021 07:38:50PM Via Free Access
    229 3 <V>:<Iss> X ZHOU and others Gonadotrope-specific Bmpr1a 229229:3:3 331–341 Research knockout mice Normal gonadotropin production and fertility in gonadotrope- specific Bmpr1a knockout mice Xiang Zhou1,2, Ying Wang1,2, Luisina Ongaro1,2, Ulrich Boehm3, Vesa Kaartinen4, Yuji Mishina4 and Daniel J Bernard1,2 1Department of Pharmacology and Therapeutics, McGill University, Montreal, Québec, Canada 2Centre for Research in Reproduction and Development, McGill University, Montreal, Québec, Canada Correspondence 3Department of Pharmacology and Toxicology, University of Saarland School of Medicine, Homburg, Germany should be addressed 4Department of Biologic and Materials Sciences, School of Dentistry, University of Michigan, Ann Arbor, to D J Bernard Michigan, USA Email [email protected] Abstract Pituitary follicle-stimulating hormone (FSH) synthesis is regulated by transforming Key Words growth factor β superfamily ligands, most notably the activins and inhibins. Bone f pituitary morphogenetic proteins (BMPs) also regulate FSHβ subunit (Fshb) expression in f FSH immortalized murine gonadotrope-like LβT2 cells and in primary murine or ovine f bone morphogenetic Endocrinology primary pituitary cultures. BMP2 signals preferentially via the BMP type I receptor, protein of BMPR1A, to stimulate murine Fshb transcription in vitro. Here, we used a Cre–lox f activin receptor-like kinase approach to assess BMPR1A’s role in FSH synthesis in mice in vivo. Gonadotrope- Journal f Cre-lox specific Bmpr1a knockout animals developed normally and had reproductive organ weights comparable with those of controls. Knockouts were fertile, with normal serum gonadotropins and pituitary gonadotropin subunit mRNA expression. Cre-mediated recombination of the floxed Bmpr1a allele was efficient and specific, as indicated by PCR analysis of diverse tissues and isolated gonadotrope cells.
    [Show full text]
  • 1714 Gene Comprehensive Cancer Panel Enriched for Clinically Actionable Genes with Additional Biologically Relevant Genes 400-500X Average Coverage on Tumor
    xO GENE PANEL 1714 gene comprehensive cancer panel enriched for clinically actionable genes with additional biologically relevant genes 400-500x average coverage on tumor Genes A-C Genes D-F Genes G-I Genes J-L AATK ATAD2B BTG1 CDH7 CREM DACH1 EPHA1 FES G6PC3 HGF IL18RAP JADE1 LMO1 ABCA1 ATF1 BTG2 CDK1 CRHR1 DACH2 EPHA2 FEV G6PD HIF1A IL1R1 JAK1 LMO2 ABCB1 ATM BTG3 CDK10 CRK DAXX EPHA3 FGF1 GAB1 HIF1AN IL1R2 JAK2 LMO7 ABCB11 ATR BTK CDK11A CRKL DBH EPHA4 FGF10 GAB2 HIST1H1E IL1RAP JAK3 LMTK2 ABCB4 ATRX BTRC CDK11B CRLF2 DCC EPHA5 FGF11 GABPA HIST1H3B IL20RA JARID2 LMTK3 ABCC1 AURKA BUB1 CDK12 CRTC1 DCUN1D1 EPHA6 FGF12 GALNT12 HIST1H4E IL20RB JAZF1 LPHN2 ABCC2 AURKB BUB1B CDK13 CRTC2 DCUN1D2 EPHA7 FGF13 GATA1 HLA-A IL21R JMJD1C LPHN3 ABCG1 AURKC BUB3 CDK14 CRTC3 DDB2 EPHA8 FGF14 GATA2 HLA-B IL22RA1 JMJD4 LPP ABCG2 AXIN1 C11orf30 CDK15 CSF1 DDIT3 EPHB1 FGF16 GATA3 HLF IL22RA2 JMJD6 LRP1B ABI1 AXIN2 CACNA1C CDK16 CSF1R DDR1 EPHB2 FGF17 GATA5 HLTF IL23R JMJD7 LRP5 ABL1 AXL CACNA1S CDK17 CSF2RA DDR2 EPHB3 FGF18 GATA6 HMGA1 IL2RA JMJD8 LRP6 ABL2 B2M CACNB2 CDK18 CSF2RB DDX3X EPHB4 FGF19 GDNF HMGA2 IL2RB JUN LRRK2 ACE BABAM1 CADM2 CDK19 CSF3R DDX5 EPHB6 FGF2 GFI1 HMGCR IL2RG JUNB LSM1 ACSL6 BACH1 CALR CDK2 CSK DDX6 EPOR FGF20 GFI1B HNF1A IL3 JUND LTK ACTA2 BACH2 CAMTA1 CDK20 CSNK1D DEK ERBB2 FGF21 GFRA4 HNF1B IL3RA JUP LYL1 ACTC1 BAG4 CAPRIN2 CDK3 CSNK1E DHFR ERBB3 FGF22 GGCX HNRNPA3 IL4R KAT2A LYN ACVR1 BAI3 CARD10 CDK4 CTCF DHH ERBB4 FGF23 GHR HOXA10 IL5RA KAT2B LZTR1 ACVR1B BAP1 CARD11 CDK5 CTCFL DIAPH1 ERCC1 FGF3 GID4 HOXA11 IL6R KAT5 ACVR2A
    [Show full text]